NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.150
-0.050 (-4.17%)
Jan 2, 2025, 4:00 PM EST - Market closed
NeuroSense Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 4.68 | 4.78 | 4.97 | 1.59 | 0.39 | 0.34 |
| Research & Development | 6.52 | 7.27 | 5.59 | 1.39 | 2.5 | 0.9 |
| Operating Expenses | 11.19 | 12.05 | 10.55 | 2.99 | 2.89 | 1.24 |
| Operating Income | -11.19 | -12.05 | -10.55 | -2.99 | -2.89 | -1.24 |
| Interest & Investment Income | - | 0.18 | 0.09 | - | - | - |
| Currency Exchange Gain (Loss) | 0.02 | 0.02 | -0.02 | -0.03 | 0.06 | 0.02 |
| Other Non Operating Income (Expenses) | 1.74 | 1.74 | -0.01 | -0.2 | -0 | -0.01 |
| Pretax Income | -11.6 | -10.11 | -10.49 | -3.22 | -2.83 | -1.22 |
| Net Income | -11.6 | -10.11 | -10.49 | -3.22 | -2.83 | -1.22 |
| Net Income to Common | -11.6 | -10.11 | -10.49 | -3.22 | -2.83 | -1.22 |
| Shares Outstanding (Basic) | 17 | 14 | 12 | 6 | 6 | 5 |
| Shares Outstanding (Diluted) | 17 | 14 | 12 | 6 | 6 | 5 |
| Shares Change (YoY) | 42.04% | 18.56% | 84.27% | 13.12% | 19.10% | - |
| EPS (Basic) | -0.66 | -0.74 | -0.91 | -0.52 | -0.51 | -0.26 |
| EPS (Diluted) | -0.66 | -0.74 | -0.91 | -0.52 | -0.51 | -0.26 |
| Free Cash Flow | - | -8.38 | -7.69 | -1.56 | -0.7 | -0.59 |
| Free Cash Flow Per Share | - | -0.61 | -0.67 | -0.25 | -0.13 | -0.13 |
| EBITDA | -11.17 | -12.03 | -10.54 | -2.98 | -2.89 | - |
| D&A For EBITDA | 0.03 | 0.02 | 0.01 | 0 | 0 | - |
| EBIT | -11.19 | -12.05 | -10.55 | -2.99 | -2.89 | -1.24 |
Source: S&P Capital IQ. Standard template.
Financial Sources.